As atopic dermatitis (AD) prevalence has increased in children over several decades, it's critical for physicians to recognize the environmental and demographic factors contributing to the change, said Jonathan Silverberg, MD, PhD, MPH.
Jonathan Silverberg, MD, PhD, MPH, is an associate professor of dermatology at George Washington University School of Medicine and Health Sciences.
Transcript:
Why is it important to quantify the prevalence of atopic dermatitis in children?
Silverberg: Prevalence is a little bit of a complicated statistic to interpret in general because it reflects not only more incident cases but it also reflects more persistent cases over time and a composite overall assessment of the state of how common a disease can be. What we've seen is that over the past 40 to 50 years, there's been this steady increase in the prevalence of atopic dermatitis and there has been some real questions about whether or not it's continuing to increase. Why that matters is severalfold: one, because this is a disease that is highly related to environmental factors so with changing environmental factors, there may be an increase in prevalence and [two] there are fascinating differences by demographic factors as well and with a growing diversification of the population, we might expect to see changes in the prevalence.
So, that's some of the background. Overall, the importance is atopic dermatitis is arguably one of, if not the most, common chronic disease of childhood. It's even more common than asthma in children. For many children it's a mild disease, but for a large subset, it's very debilitating and chronic. These are patients that are really suffering. So, from a resource allocation standpoint and from an understanding of how commonly different medications may be used in a therapeutic landscape, these are all very important applications of where prevalence comes into play.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
Dermatologists Advocating for Inclusive Hair Loss Research and Treatment in the African Diaspora
March 26th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.
Read More